Market Research Logo

Global Dyslipidemia Drugs Market 2017-2021

Global Dyslipidemia Drugs Market 2017-2021

About Dyslipidemia Drugs

Lipid refers to fat comprising proteins and carbohydrates. Cholesterol and triglycerides are lipids that are stored in the human body and serve as a source of energy. Dyslipidaemia is the imbalance in the lipid level in the bloodstream. It is characterized by high levels of total cholesterol and low-density lipoprotein cholesterol (LDL-C) in the blood. High cholesterol levels can cause cardiovascular diseases (CVD) such as stroke and atherosclerosis. The typical range of total blood cholesterol is 140-200 mg/dL. Blood cholesterol contains individual components such as LDL-C and high-density lipoprotein cholesterol (HDL-C). Low-density lipoprotein (LDL) carries cholesterol to the body while high-density lipoprotein (HDL) removes cholesterol from the cells by reversing cholesterol transport to the liver. Due to their distinct roles, these components are individually assessed to determine the dyslipidemic status of an individual.

Technavio’s analysts forecast the global dyslipidemia drugs market to grow at a CAGR of 5.27% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global dyslipidemia drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Dyslipidemia Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • AstraZeneca
  • Merck
  • Pfizer
  • Sanofi
Other prominent vendors
  • Alnylam Pharmaceuticals
  • Amarin Corporation
  • Amgen
  • Bristol-Myers Squibb
  • Catabasis Pharmaceuticals
  • Cerenis
  • Cipla
  • CJ HealthCare
  • CKD Bio
  • Daewoong Pharmaceutical
  • Daiichi Sankyo
  • Eli Lilly
  • Esperion Therapeutics
  • GlaxoSmithKline
  • JW Pharmaceuticals
  • Kadmon Pharmaceuticals
  • Lupin Pharmaceuticals
Market driver
  • Change in ATP guidelines for management of hypercholesterolemia.
  • For a full, detailed list, view our report
Market challenge
  • Drawbacks associated with current therapies.
  • For a full, detailed list, view our report
Market trend
  • Increased uptake of OTC drugs.
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


  • Executive summary
  • Scope of the report
  • Research Methodology
  • Introduction
    • Key market highlights
  • An overview of dyslipidemia
    • Table Key customer segments
  • Pipeline analysis
    • Table Overview of phase III pipeline molecules in global dyslipidemia drugs market
    • Table Pipeline analysis
  • Market landscape
    • Market overview
      • Table Global dyslipidemia drugs market snapshot 2016
      • Table Global dyslipidemia drugs market 2016-2021 ($ millions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by drug class
    • Table Global dyslipidemia drugs market by drug class
    • Statins
      • Table Global statin market 2016-2021 ($ millions)
    • Cholesterol absorption inhibitors
      • Table Global cholesterol absorption inhibitors market 2016-2021 ($ millions)
    • Dyslipidemia injectables
      • Table Global dyslipidemia injectables market 2016-2021 ($ millions)
    • Others
  • Geographical segmentation
    • Table Global dyslipidemia drugs market by geography 2016 and 2021
    • Table Dyslipidemia drugs market revenue by geography 2016-2021 ($ millions)
    • Dyslipidemia drugs market in Americas
      • Table Market scenario in Americas
      • Table Dyslipidemia drugs market in Americas 2016-2021 ($ millions)
    • Dyslipidemia drugs market in EMEA
      • Table Market scenario in EMEA
      • Table Dyslipidemia drugs market in the EMEA 2016-2021 ($ millions)
    • Dyslipidemia drugs market in APAC
      • Table Market scenario in APAC
      • Table Dyslipidemia drugs market in APAC 2016-2021 ($ millions)
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Population aged 60 years and over: World and developed and developing regions (millions)
    • Impact of drivers on key customer segments
      • Table Impact of drivers
    • Market challenges
    • Impact of challenges on key customer segments
      • Table Impact of challenges
  • Market trends
    • Increasing use of statins
    • Combination therapies
    • Increased uptake of OTC drugs
  • Vendor landscape
    • Competitive scenario
      • Table Competitive structure analysis of global dyslipidemia drugs market 2016
      • Table Competitive analysis of global dyslipidemia drugs market 2016
      • Table Market penetration of various players in global dyslipidemia drugs market 2016
  • Key vendor analysis
    • Aegerion Pharmaceuticals
      • Table Aegerion Pharmaceuticals: Key highlights
      • Table Aegerion Pharmaceuticals: Strength assessment
      • Table Aegerion Pharmaceuticals: Strategy assessment
      • Table Aegerion Pharmaceuticals: Opportunity assessment
    • AstraZeneca
      • Table AstraZeneca: Key highlights
      • Table AstraZeneca: Strength assessment
      • Table AstraZeneca: Strategy assessment
      • Table AstraZeneca: Opportunity assessment
    • Merck
      • Table Merck: Key highlights
      • Table Merck: Strength assessment
      • Table Merck: Strategy assessment
      • Table Merck: Opportunity assessment
    • Pfizer
      • Table Pfizer: Key highlights
      • Table Pfizer: Strength assessment
      • Table Pfizer: Strategy assessment
      • Table Pfizer: Opportunity assessment
    • Sanofi
      • Table Sanofi: Key highlights
      • Table Sanofi: Strength assessment
      • Table Sanofi: Strategy assessment
      • Table Sanofi: Opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report